AZ's Alexion Acquisition Looks Astute Bit Of Business
Offers $39bn For Rare Disease Drug Pioneer
Executive Summary
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
You may also be interested in...
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
AstraZeneca Clears Final Hurdle To Seal Alexion Takeover
Antitrust authorities in the UK have followed their counterparts in the EU, Japan and the US to approve the AstraZeneca and Alexion link-up, the biggest pharma M&A deal of 2020.
Apellis' Empaveli Poised To Give Soliris A Run In PNH
The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.